San Raffaele
No hidden fees – just official clinic prices. Pay at the clinic for Spinal Muscular Atrophy treatment and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Spinal Muscular Atrophy treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Spinal Muscular Atrophy treatment journey.
Italy approves three disease-modifying treatments for Spinal Muscular Atrophy (SMA). These include Nusinersen (Spinraza), Onasemnogene Abeparvovec (Zolgensma), and Risdiplam (Evrysdi). The Italian Medicines Agency (AIFA) reimburses these therapies through the National Health System. Access depends on genetic profile and SMA type.
Bookimed Expert Insight: San Raffaele Hospital in Milan is a primary destination for genetic care. It holds IRCCS accreditation for combining clinical assistance with research. This status is rare in Italy. Facilities with this credential often manage complex cases using advanced diagnostic research unavailable at standard regional centers.
Patient Consensus: Patients value the convenience of oral Risdiplam to avoid repeated hospital procedures. Many note that while Italy is organized, therapy shifts require time for official authorizations and specialist sign-off.
Prominent Italian centers for Spinal Muscular Atrophy (SMA) include NeMO Clinical Centers and university hospitals like San Raffaele. These IRCCS-accredited facilities offer AIFA-authorized gene therapies and splicing modifiers. Specialized hubs in Milan, Rome, and Naples coordinate multidisciplinary care and advanced clinical trials.
Bookimed Expert Insight: San Raffaele maintains a significant edge in genetic research with IRCCS accreditation and 52,000 annual operations. We see a trend where patients prioritize these research-heavy institutions because they often house the specific multidisciplinary teams needed for complex SMA follow-up. Italy ranks 7th globally in our network for requests, reflecting its high expertise in rare genetic conditions.
Patient Consensus: Patients note it is vital to find a center that coordinates neurology, pulmonology, and rehabilitation in one team. They emphasize that the fastest access to a diagnostic pathway matters more than the hospital's distance from home.
Newborn screening for SMA is not yet nationwide or mandatory across Italy. Availability depends on regional legislation and local pilot programs. While covering 95% of births, newborns in Calabria, Molise, and Umbria lack access to these screening initiatives under current local health policies.
Bookimed Expert Insight: While Italy ranks 7th globally in our network, genetic disease treatment is concentrated in specific research hubs. San Raffaele in Milan maintains IRCCS accreditation for its clinical research. This status is limited to a small number of elite Italian institutions. Patients seeking presymptomatic SMA care often target these northern academic centers. These facilities perform over 52,000 operations annually and lead the country in genetic research.
Adults with Spinal Muscular Atrophy can receive treatment in Italy. The Italian Medicines Agency (AIFA) reimburses therapies for adults through the national health system. Access is available for SMA types 1, 2, and 3. Treatment occurs at authorized neuromuscular reference centers.
Bookimed Expert Insight: While Italy has 18 active clinics on our platform, San Raffaele stands out for its high volume. It handles 300,000 patients annually and holds IRCCS accreditation. This research hospital status is vital for adult SMA patients. These institutions often have the specialized infrastructure needed for complex adult neurological care.
Patient Consensus: Patients note that navigating the bureaucratic process is often the biggest hurdle. Access sometimes depends on the specific regional health authority. They emphasize that early entry into a specialized clinic is the most important step for approval.
Italian spinal muscular atrophy referral centers strictly integrate complementary rehabilitative services with pharmacological therapies. National care standards dictate that drug-based treatments require parallel physical and respiratory rehabilitation. This multidisciplinary model facilitates optimal functional outcomes for patients receiving gene therapy or disease-modifying medications.
Bookimed Expert Insight: Italian centers like San Raffaele in Milan operate as IRCCS accredited research institutions. This designation ensures that clinical rehabilitation protocols are directly informed by active genetic research. Patients benefit because their physical therapy plans evolve alongside the newest pharmacological breakthroughs. Focus on centers with these specific research credentials for the most advanced care coordination.
Patient Consensus: Patients emphasize that pharmacological treatment never replaces the need for consistent physical therapy. They focus on finding centers that provide individualized respiratory and posture plans instead of generic advice.
Italy reimburses Zolgensma under the National Health Service (SSN) framework. The Italian Medicines Agency (AIFA) manages this through a performance-based agreement. Payment depends on patient outcomes. Clinical benchmarks are tracked at 12, 24, 36, and 48 months post-infusion.
Bookimed Expert Insight: Italian medicine access relies heavily on specific research designations. San Raffaele in Milan holds IRCCS accreditation from the Ministry of Health. This status means the hospital combines clinical care with advanced genetic research. Such centers often bridge the gap between national reimbursement and technical delivery for SMA.
Patient Consensus: Families emphasize that finding an SSN-connected neuromuscular center is vital for evaluation. They note that genetic confirmation must happen quickly to meet narrow treatment windows.